J.B. Hunt Transportation Services, Inc. (JBHT - Free Report) reported first-quarter 2018 earnings per share of $1.07, missing the Zacks Consensus Estimate of $1.09.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for J.B. Hunt depicted a healthy picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for first-quarter earnings being revised 1.9% upward over the last 90 days.
However, J.B. Hunt has an unimpressive earnings surprise history. The company has surpassed the Zacks Consensus Estimate in only two of the last four quarters with an average miss of 0.7%.
Revenues Higher Than Expected
J.B. Hunt recorded revenues of $1,948.2 million, which surpassed the Zacks Consensus Estimate of $1,872.1 million.
Key Q1 Statistics: During the quarter, the company did not repurchase shares. As on Mar 31, 2018, the company had around $521 million shares remaining under its share buyback program. Operating income in the first quarter increased 12.9% to $168.8 million (on a reported basis). Outstanding debt was $1 billion at the end of the quarter.
Zacks Rank: Currently, J.B. Hunt carries a Zacks Rank #3 (Hold) which is subject to change following the earnings announcement. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this J.B. Hunt earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
J.B. Hunt Transportation Services, Inc. (JBHT - Free Report) reported first-quarter 2018 earnings per share of $1.07, missing the Zacks Consensus Estimate of $1.09.
How Was the Estimate Revision Trend?
Investors should note that the earnings estimate revisions for J.B. Hunt depicted a healthy picture prior to the earnings release. The stock had seen the Zacks Consensus Estimate for first-quarter earnings being revised 1.9% upward over the last 90 days.
However, J.B. Hunt has an unimpressive earnings surprise history. The company has surpassed the Zacks Consensus Estimate in only two of the last four quarters with an average miss of 0.7%.
Revenues Higher Than Expected
J.B. Hunt recorded revenues of $1,948.2 million, which surpassed the Zacks Consensus Estimate of $1,872.1 million.
Key Q1 Statistics: During the quarter, the company did not repurchase shares. As on Mar 31, 2018, the company had around $521 million shares remaining under its share buyback program. Operating income in the first quarter increased 12.9% to $168.8 million (on a reported basis). Outstanding debt was $1 billion at the end of the quarter.
Zacks Rank: Currently, J.B. Hunt carries a Zacks Rank #3 (Hold) which is subject to change following the earnings announcement. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this J.B. Hunt earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on JBHT - FREE